FGEN Share Price Performance
US$11.00
3.33 (43.32%)
74.4% undervalued intrinsic discount
US$43.00
Fair Value
Price US$11.00
AnalystConsensusTarget US$43.00
Fair ValueUS$43.00
Share PriceUS$11.00
74.4% undervalued intrinsic discount
FibroGen, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FGEN Community Narratives
AN
Fair Value US$43 74.4% undervalued intrinsic discount
Clinical Trials And Regulatory Advances Will Open US Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Clinical Trials And Regulatory Advances Will Open US Markets
Key Takeaways Advancing precision oncology and rare disease treatments positions the company for future revenue growth and strong market opportunities in underserved populations. Liquidity improvements and strategic pipeline diversification reduce financial risk while enhancing long-term earnings stability and optionality.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$43
74.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-3.88% p.a.
Profit Margin
16.06%
Future PE
216.47x
Share price in 2028
US$55.54
Snowflake Analysis
FibroGen, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 10, 2025
- -21.61
- -394.13%
- -1,189.84%
- -51.4%
About FGEN
- Founded
- 1993
- Employees
- 225
- CEO
- WebsiteView website
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
